Cargando…
Therapy-related acute myeloid leukemia following treatment of lymphoid malignancies
Therapy-related acute myeloid leukemia (t-AML) is a heterogeneous entity most frequently related to breast cancer or lymphoproliferative diseases (LD). Population-based studies have reported an increased risk of t-AML after treatment of lymphomas. The aim of this study was to describe the characteri...
Autores principales: | , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Impact Journals LLC
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5349887/ https://www.ncbi.nlm.nih.gov/pubmed/27852053 http://dx.doi.org/10.18632/oncotarget.13262 |
_version_ | 1782514549821276160 |
---|---|
author | Bertoli, Sarah Sterin, Arthur Tavitian, Suzanne Oberic, Lucie Ysebaert, Loïc Bouabdallah, Reda Vergez, François Sarry, Audrey Bérard, Emilie Huguet, Françoise Laurent, Guy Prébet, Thomas Vey, Norbert Récher, Christian |
author_facet | Bertoli, Sarah Sterin, Arthur Tavitian, Suzanne Oberic, Lucie Ysebaert, Loïc Bouabdallah, Reda Vergez, François Sarry, Audrey Bérard, Emilie Huguet, Françoise Laurent, Guy Prébet, Thomas Vey, Norbert Récher, Christian |
author_sort | Bertoli, Sarah |
collection | PubMed |
description | Therapy-related acute myeloid leukemia (t-AML) is a heterogeneous entity most frequently related to breast cancer or lymphoproliferative diseases (LD). Population-based studies have reported an increased risk of t-AML after treatment of lymphomas. The aim of this study was to describe the characteristics and outcome of 80 consecutive cases of t-AML following treatment of LD. t-AML accounted for 2.3% of all AML cases, occurred 60 months after LD diagnosis, and were characterized by a high frequency of FAB M6 AML and poor-risk cytogenetic abnormalities. Time to t-AML diagnosis was influenced by patient age, type of LD, and treatment. Among the 48 t-AML patients treated with intensive chemotherapy, median overall survival (OS) was 7.7 months compared to 26.1 months in de novo, 4.2 months in post-myeloproliferative neoplasm, 9.4 months in post-myelodysplastic syndrome, 8.6 months in post-chronic myelomonocytic leukemia AML, 13.4 months in t-AML secondary to the treatment of solid cancer, and 14.7 months in breast cancer only. OS of post-LD t-AML patients was significantly influenced by age, performance status, myelodysplastic syndrome prior to LD/t-AML, and treatment regimen for LD. Thus, t-AML following lymphoid malignancies treatment should be considered as very high-risk secondary AML. New treatment strategies in patients with LD/t-AML are needed urgently. |
format | Online Article Text |
id | pubmed-5349887 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2016 |
publisher | Impact Journals LLC |
record_format | MEDLINE/PubMed |
spelling | pubmed-53498872017-04-06 Therapy-related acute myeloid leukemia following treatment of lymphoid malignancies Bertoli, Sarah Sterin, Arthur Tavitian, Suzanne Oberic, Lucie Ysebaert, Loïc Bouabdallah, Reda Vergez, François Sarry, Audrey Bérard, Emilie Huguet, Françoise Laurent, Guy Prébet, Thomas Vey, Norbert Récher, Christian Oncotarget Research Paper Therapy-related acute myeloid leukemia (t-AML) is a heterogeneous entity most frequently related to breast cancer or lymphoproliferative diseases (LD). Population-based studies have reported an increased risk of t-AML after treatment of lymphomas. The aim of this study was to describe the characteristics and outcome of 80 consecutive cases of t-AML following treatment of LD. t-AML accounted for 2.3% of all AML cases, occurred 60 months after LD diagnosis, and were characterized by a high frequency of FAB M6 AML and poor-risk cytogenetic abnormalities. Time to t-AML diagnosis was influenced by patient age, type of LD, and treatment. Among the 48 t-AML patients treated with intensive chemotherapy, median overall survival (OS) was 7.7 months compared to 26.1 months in de novo, 4.2 months in post-myeloproliferative neoplasm, 9.4 months in post-myelodysplastic syndrome, 8.6 months in post-chronic myelomonocytic leukemia AML, 13.4 months in t-AML secondary to the treatment of solid cancer, and 14.7 months in breast cancer only. OS of post-LD t-AML patients was significantly influenced by age, performance status, myelodysplastic syndrome prior to LD/t-AML, and treatment regimen for LD. Thus, t-AML following lymphoid malignancies treatment should be considered as very high-risk secondary AML. New treatment strategies in patients with LD/t-AML are needed urgently. Impact Journals LLC 2016-11-10 /pmc/articles/PMC5349887/ /pubmed/27852053 http://dx.doi.org/10.18632/oncotarget.13262 Text en Copyright: © 2016 Bertoli et al. http://creativecommons.org/licenses/by/3.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. |
spellingShingle | Research Paper Bertoli, Sarah Sterin, Arthur Tavitian, Suzanne Oberic, Lucie Ysebaert, Loïc Bouabdallah, Reda Vergez, François Sarry, Audrey Bérard, Emilie Huguet, Françoise Laurent, Guy Prébet, Thomas Vey, Norbert Récher, Christian Therapy-related acute myeloid leukemia following treatment of lymphoid malignancies |
title | Therapy-related acute myeloid leukemia following treatment of lymphoid malignancies |
title_full | Therapy-related acute myeloid leukemia following treatment of lymphoid malignancies |
title_fullStr | Therapy-related acute myeloid leukemia following treatment of lymphoid malignancies |
title_full_unstemmed | Therapy-related acute myeloid leukemia following treatment of lymphoid malignancies |
title_short | Therapy-related acute myeloid leukemia following treatment of lymphoid malignancies |
title_sort | therapy-related acute myeloid leukemia following treatment of lymphoid malignancies |
topic | Research Paper |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5349887/ https://www.ncbi.nlm.nih.gov/pubmed/27852053 http://dx.doi.org/10.18632/oncotarget.13262 |
work_keys_str_mv | AT bertolisarah therapyrelatedacutemyeloidleukemiafollowingtreatmentoflymphoidmalignancies AT sterinarthur therapyrelatedacutemyeloidleukemiafollowingtreatmentoflymphoidmalignancies AT tavitiansuzanne therapyrelatedacutemyeloidleukemiafollowingtreatmentoflymphoidmalignancies AT obericlucie therapyrelatedacutemyeloidleukemiafollowingtreatmentoflymphoidmalignancies AT ysebaertloic therapyrelatedacutemyeloidleukemiafollowingtreatmentoflymphoidmalignancies AT bouabdallahreda therapyrelatedacutemyeloidleukemiafollowingtreatmentoflymphoidmalignancies AT vergezfrancois therapyrelatedacutemyeloidleukemiafollowingtreatmentoflymphoidmalignancies AT sarryaudrey therapyrelatedacutemyeloidleukemiafollowingtreatmentoflymphoidmalignancies AT berardemilie therapyrelatedacutemyeloidleukemiafollowingtreatmentoflymphoidmalignancies AT huguetfrancoise therapyrelatedacutemyeloidleukemiafollowingtreatmentoflymphoidmalignancies AT laurentguy therapyrelatedacutemyeloidleukemiafollowingtreatmentoflymphoidmalignancies AT prebetthomas therapyrelatedacutemyeloidleukemiafollowingtreatmentoflymphoidmalignancies AT veynorbert therapyrelatedacutemyeloidleukemiafollowingtreatmentoflymphoidmalignancies AT recherchristian therapyrelatedacutemyeloidleukemiafollowingtreatmentoflymphoidmalignancies |